UK Markets closed

Molecular Partners AG (MOLN)

NasdaqGS - NasdaqGS Delayed price. Currency in USD
Add to watchlist
6.50-0.13 (-1.96%)
At close: 03:36PM EST
6.52 0.00 (0.00%)
After hours: 04:00PM EST

Molecular Partners AG

Wagistrasse 14
Schlieren 8952
41 44 755 77 00

Full-time employees163

Key executives

NameTitlePayExercisedYear born
Dr. Patrick Amstutz Ph.D.Co-Founder, CEO, Member of Management Board & Director676.04kN/A1975
Dr. Michael Tobias Stumpp Ph.D.Co-Founder, Exec. VP of Projects & Member of Management BoardN/AN/A1972
Mr. Andreas Emmenegger E.M.B.A.AdvisorN/AN/A1966
Mr. Alexander ZurcherCOO & Member of Management BoardN/AN/AN/A
Dr. Nicolas Leupin M.B.A., Ph.D., M.D., MBAChief Medical Officer & Member of Management BoardN/AN/A1973
Ms. Renate GloggnerExec. VP of People & Community and Member of Management BoardN/AN/AN/A
Mr. Daniel Steiner Ph.D.Sr. VP of ResearchN/AN/AN/A
Mr. Seth D. LewisSr. VP of Investor Relations, Communications & StrategyN/AN/AN/A
Mr. Julien Gander L.L.M.Gen. Counsel, Sr. VP of Legal & Sec. of the BoardN/AN/AN/A
Mr. Thomas SchwerzmannVP of HRN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Corporate governance

Molecular Partners AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.